CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Oral EVO756 300 mg QD +1 moredrug
Likely dose
Oral EVO756 300 mg QDfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06603220
NCT06603220Phase 2Completed
CompareCT.gov

An Open Label Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria

Evommune, Inc.·interventional·Posted Sep 19, 2024·Updated May 19, 2026

In Brief

A Phase 2 clinical trial evaluating Oral EVO756 300 mg QD and Oral EVO756 50 mg BID for Chronic Inducible Urticaria. Completed, enrolled 30 participants across 18 sites.

Detailed Summary

This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Inducible Urticaria
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20252026
First PostedSep 19, 2024
Enrollment StartAug 14, 2024
Primary CompletionMay 8, 2025
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 1.8 years ago

Interventions

Oral EVO756 300 mg QDdrug

Oral EVO756, 300 mg once daily

Oral EVO756 50 mg BIDdrug

Oral EVO756 50 mg twice daily